newsfilter
← Latest News
GlobeNewswire·

RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

RNXT
  • RenovoRx appointed Mark Voll as Chief Financial Officer effective February 1, 2026.
  • Voll brings over three decades of financial leadership experience, having previously served as CFO for multiple public technology companies.
  • His career includes guiding companies through IPOs & acquisitions, including Techwell, Montage Technology, & Aquantia Corporation.
  • Voll will lead stockholder communications, budgeting, strategic planning, & operations to support the commercialization of RenovoCath.
  • RenovoRx is advancing its Phase III TIGeR-PaC clinical trial for the drug-device combination IAG (intra-arterial gemcitabine via RenovoCath).
  • The company generated approximately $900,000 in revenue from RenovoCath sales during the first nine months of 2025.
  • RenovoRx received its first commercial purchase orders for RenovoCath in December 2024 & reports repeat orders from high-volume NCI-designated centers.
  • IAG has received Orphan Drug Designation for pancreatic cancer & bile duct cancer, granting seven years of market exclusivity upon approval.
  • Ronald B. Kocak will remain with RenovoRx as principal accounting officer for a transitional period alongside Executive Director of Finance Lilly Huang.
  • RenovoRx is a life sciences company developing targeted oncology therapies & commercializing the FDA-cleared RenovoCath drug-delivery device.